By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Antidotes > Leucovorin (injection) > Leucovorin Dosage
Antidotes
https://themeditary.com/dosage-information/leucovorin-dosage-10345.html

Leucovorin Dosage

Drug Detail:Leucovorin (injection) (Leucovorin (injection) [ loo-koe-vor-in ])

Drug Class: Antidotes

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Colorectal Cancer

200 mg/m2, by slow IV injection (minimum 3 minutes), followed by 5-fluorouracil (the manufacturer product information should be consulted), once a day for 5 days
OR
20 mg/m2, IV, followed by 5-fluorouracil (the manufacturer product information should be consulted), once a day for 5 days

Comments:

  • Do not be mix in the same infusion as 5-fluorouracil; a precipitate may form.
  • May repeat 5 day treatment course at 4 week (28 day) intervals for 2 courses, then repeat at 4 to 5 week (28 to 35 day) intervals provided the patient is completely recovered from toxicities of the prior course.

Use: For use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.

Usual Adult Dose for Methotrexate Rescue

Leucovorin Rescue:
15 mg (approximately 10 mg/m2), orally, IV, or IM, every 6 hours for 10 doses; start 24 hours after beginning of methotrexate infusion (based on a methotrexate dose of 12 to 15 g/m2 IV over 4 hours)

Impaired Methotrexate Elimination or Inadvertent Overdosage:
10 mg/m2 orally, IV, or IM, every 6 hours until methotrexate level is less than 10(-8) mol

Comments:

  • Determine serum creatinine and methotrexate levels at least once a day.
  • Continue leucovorin, hydration, and urinary alkalization until methotrexate levels are below 5 x 10(-8) mol.
  • Give parenterally if gastrointestinal toxicity, nausea, or vomiting are present.

Uses: Leucovorin rescue after high dose methotrexate therapy; diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages.

Usual Adult Dose for Methotrexate Overdosage

Leucovorin Rescue:
15 mg (approximately 10 mg/m2), orally, IV, or IM, every 6 hours for 10 doses; start 24 hours after beginning of methotrexate infusion (based on a methotrexate dose of 12 to 15 g/m2 IV over 4 hours)

Impaired Methotrexate Elimination or Inadvertent Overdosage:
10 mg/m2 orally, IV, or IM, every 6 hours until methotrexate level is less than 10(-8) mol

Comments:

  • Determine serum creatinine and methotrexate levels at least once a day.
  • Continue leucovorin, hydration, and urinary alkalization until methotrexate levels are below 5 x 10(-8) mol.
  • Give parenterally if gastrointestinal toxicity, nausea, or vomiting are present.

Uses: Leucovorin rescue after high dose methotrexate therapy; diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages.

Usual Adult Dose for Megaloblastic Anemia

Up to 1 mg, IV or IM, once a day

Comments:

  • There is no evidence that doses above 1 mg daily have greater efficacy; additionally, urinary folate loss becomes roughly logarithmic as the amount administered exceeds 1 mg.

Use: Treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible

Usual Adult Dose for Folic Acid Antagonist Overdose

5 to 15 mg orally once a day

Use: Diminish the toxicity and counteract the effects of inadvertent overdosages of folic acid antagonists.

Usual Adult Dose for Pneumocystis Pneumonia

Treatment of pneumocystis pneumonia is not is not a labeled indication.

20 mg/m2 or 0.5 mg/kg, IV or orally, every 6 hours, continued for 3 days after last trimetrexate dose

Comments:

  • Use in combination with trimetrexate.

Use: Treatment of pneumocystis pneumonia in HIV infected patients

Usual Adult Dose for Pneumocystis Pneumonia Prophylaxis

Prophylaxis of pneumocystis pneumonia is not a labeled indication.

25 mg, orally, once a week, in combination with dapsone and pyrimethamine

Comments:

  • Prophylaxis in HIV infected patients usually begins when the CD4+ count is less than 200 cells/mm or for a history of oropharyngeal candidiasis.
  • Prophylaxis is usually discontinued when CD4+ count is 200 cells/mm or higher for 3 months.

Use: Pneumocystis pneumonia prophylaxis in immunocompromised patients

Usual Adult Dose for Toxoplasmosis

Use in the treatment of toxoplasmosis is not a labeled indication.

Ocular toxoplasmosis:
5 to 25 mg orally, IV, or IM, with each dose of pyrimethamine

Acute/primary treatment of toxoplasma encephalitis in AIDS patients:
Standard dose: 10 to 20 mg, orally, IM, or IV, once a day, during and for 1 week after pyrimethamine treatment
Maximum dose: 50 mg once a day

Use: Toxoplasmosis treatment

Usual Pediatric Dose for Colorectal Cancer

200 mg/m2, by slow IV injection (minimum 3 minutes), followed by 5-fluorouracil (the manufacturer product information should be consulted), once a day for 5 days
OR
20 mg/m2, IV, followed by 5-fluorouracil (the manufacturer product information should be consulted), once a day for 5 days

Comments:

  • Do not be mix in the same infusion as 5-fluorouracil; a precipitate may form.
  • May repeat 5 day treatment course at 4 week (28 day) intervals for 2 courses, then repeat at 4 to 5 week (28 to 35 day) intervals provided the patient is completely recovered from toxicities of the prior course.

Use: For use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.

Usual Pediatric Dose for Methotrexate Rescue

Leucovorin Rescue:
15 mg (approximately 10 mg/m2), orally, IV, or IM, every 6 hours for 10 doses; start 24 hours after beginning of methotrexate infusion (based on a methotrexate dose of 12 to 15 g/m2 IV over 4 hours)

Impaired Methotrexate Elimination or Inadvertent Overdosage:
10 mg/m2 orally, IV, or IM, every 6 hours until methotrexate level is less than 10(-8) mol

Comments:

  • Determine serum creatinine and methotrexate levels at least once a day.
  • Continue leucovorin, hydration, and urinary alkalization until methotrexate levels are below 0.05 micromol.
  • Give parenterally if gastrointestinal toxicity, nausea, or vomiting are present.

Uses: Leucovorin rescue after high dose methotrexate therapy; diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages.

Usual Pediatric Dose for Megaloblastic Anemia

Up to 1 mg, IV or IM, once a day

Comments:

  • There is no evidence that doses above 1 mg daily have greater efficacy; additionally, urinary folate loss becomes roughly logarithmic as the amount administered exceeds 1 mg.

Use: Treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible

Usual Pediatric Dose for Folic Acid Antagonist Overdose

5 to 15 mg orally once a day

Use: Diminish the toxicity and counteract the effects of inadvertent overdosages of folic acid antagonists.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Leucovorin Rescue for Methotrexate (MTX):

  • Normal MTX elimination (MTX approximately 10 micromol 24 hours after administration, 1 micromol at 48 hours, and less than 0.2 micromol at 72 hours): Leucovorin 15 mg oral, IM, or IV every 6 hours for 60 hours (10 doses)
  • Delayed late MTX elimination (MTX above 0.2 micromol at 72 hours, and more than 0.05 micromol at 96 hours): Continue 15 mg orally, IM, or IV every 6 hours until MTX level is under 0.05 micromol
  • Delayed early MTX elimination and/or acute renal injury (MTX 50 micromol or higher at 24 hours, or 5 micromol at 48 hours, OR a 100% or greater increase in serum creatinine at 24 hours): 150 mg leucovorin IV every 3 hours, until MTX is less than 1 micromol; then 15 mg IV every 3 hours until MTX is less than 0.05 micromol.
Comments:
  • Patients with delayed early methotrexate elimination are likely to develop reversible renal failure; continue hydration, and urinary alkalization, and close monitoring of fluid and electrolytes, in addition to leucovorin, until MTX level is below 0.05 micromol and renal failure has resolved.
  • Abnormalities in MTX elimination or renal function, which are significant but less severe than abnormalities described above, may or may not be associated with significant clinical toxicity.
  • If significant clinical toxicity is observed, extend leucovorin rescue for an additional 24 hours (total of 14 doses over 84 hours) in subsequent courses of therapy.
  • Consider the possibility that the patient is taking other medications which interact with MTX when laboratory abnormalities or clinical toxicities are observed.

Impaired Methotrexate Elimination or Inadvertent Overdosage:
  • If the 24 hour serum creatinine has increased 50% over baseline, or if the 24 hour MTX level is higher than 9 x 10(-7) mol, increase leucovorin dose to 100 mg/m2 IV every 3 hours until MTX level is less than 10(-8) mol.
  • Hydration and urinary alkalinization should be used concomitantly with leucovorin.

Colorectal Cancer:
  • After the initial treatment, adjust the dosage of 5-fluorouracil based on patient tolerance and prior treatment course.
  • Do not adjust leucovorin dose for toxicity.

Dialysis

Data not available

Other Comments

Administration advice:

  • Do not administer intrathecally; may be harmful or fatal if given intrathecally.
  • Because of the calcium content of the solution, no more than 160 mg should be injected intravenously per minute (16 mL of a 10 mg/mL, or 8 mL of a 20 mg/mL solution per minute).

Reconstitution/preparation techniques:
  • Because of the benzyl alcohol in certain diluents, when administering doses greater than 10 mg/m2, reconstitute with Sterile Water for Injection, USP, and use immediately.

IV compatibility:
  • Do not mix in the same infusion as fluorouracil; a precipitate may form.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by